Drugs / ASP546C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07488676 | May 2026 → Jul 2029 expected | gastroesophageal adenocarcinoma, pancreatic adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Evopoint Biosciences Inc. | Results 信诺维携多项核心管线最新临床前研究结果亮相2026 AACR evopointbio.com ↗
临床前研究显示，XNW27011能特异性结合高表达CLDN 18.2的肿瘤细胞，并在多种胃癌和胰腺癌的异种移植模型（CDX及PDX模型）中，于低剂量下即可实现显著的肿瘤部分或完全消退。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Evopoint Biosciences Inc. | 信诺维携多项核心管线最新临床前研究结果亮相2026 AACR evopointbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP546C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07488676 ↗ |
| Route | Intravenous | “Intravenous administration” NCT07488676 ↗ |